By using cells expressing the constitutively active STAT3(Y640F) mutant as a tool to study hyperactive STAT3, we show that small molecule inhibitors targeting CSNK2, CDK8, DDR2 and CDC7 may be used to target hyperactive STAT3 in cancer cells and warrant further validation of these targets in cancer models with STAT3 hyperactivity. The gene discussed is STAT3; the disease is cancer.